Exp Clin Endocrinol Diabetes 2020; 128(11): 703-708
DOI: 10.1055/a-0998-8035
Article

Long-term Outcome of Subacute Thyroiditis

Julia Görges
1   Innere Medizin, Gastroenterologie und Kardiologie, Evangelisches Amalie Sieveking-Krankenhaus, Hamburg, Germany
2   Center for Endocrine and Metabolic Disorders, Reproductive and Prenatal Medicine, Endokrinologikum Hamburg Betriebsgesellschaft mbH, Hamburg, Germany
,
Jan Ulrich
2   Center for Endocrine and Metabolic Disorders, Reproductive and Prenatal Medicine, Endokrinologikum Hamburg Betriebsgesellschaft mbH, Hamburg, Germany
3   Innere Medizin, Gastroenterologie und Diabetologie, Asklepios Klinik Sankt Georg, Hamburg, Germany
,
Christoph Keck
2   Center for Endocrine and Metabolic Disorders, Reproductive and Prenatal Medicine, Endokrinologikum Hamburg Betriebsgesellschaft mbH, Hamburg, Germany
,
Dirk Müller-Wieland
4   Universitatsklinikum Aachen, Aachen, Germany
,
Sven Diederich
5   MVZ Medicover Berlin-Mitte, Innere Medizin, Endokrinologie, Andrologie, Berlin, Germany
,
Onno E. Janssen
2   Center for Endocrine and Metabolic Disorders, Reproductive and Prenatal Medicine, Endokrinologikum Hamburg Betriebsgesellschaft mbH, Hamburg, Germany
› Author Affiliations

Abstract

Background Subacute thyroiditis (SAT) is a rare inflammatory disease that presents diagnostic challenges. The underlying pathophysiology and prediction of outcomes are elusive. We investigated the long-term follow-up of SAT for up to 30 years and determined predictors for later hypothyroidism.

Methods SAT outcome data from 127 patients (age: 47.6 ± 11.0 yrs., BMI: 24.7±4.8 kg/m²) were analyzed retrospectively. Patients with pre-existing and known causes of hypothyroidism unrelated to SAT were excluded. We also excluded patients without an accelerated erythrocyte sedimentation rate. SAT outcome parameters included anterior neck pain or tenderness of the thyroid, inflammation markers, hypoechoic areas in thyroid ultrasound, hyperthyroidism, fine-needle aspiration, and thyroid scan. Pre-treatment TSH-levels, gender, age, ultrasound findings, anti-thyroid antibodies and markers of inflammation were considered as possible predictors of SAT outcome.

Results More than 26.8% of SAT patients developed permanent hypothyroidism within 3 years of treatment. The patient groups later developing hypothyroidism did not differ in age, BMI, pre-treatment TSH levels or initial dosage of prednisolone treatment. However, high cumulative doses of prednisolone were associated with a higher prevalence of hypothyroidism. Also, women were more likely to develop hypothyroidism (OR: 3.18 (95% CI: 1.14–8.65); p=0.0176).

Conclusions Our study suggests that one-quarter of patients with SAT develop hypothyroidism in the long-term. Hypothyroidism was predicted by high cumulative doses of prednisolone treatment and female gender. The reported lower prevalence of hypothyroidism in other countries may represent the faster establishment of diagnosis, different treatment protocols, or lower susceptibility to loss of thyroid function. Swift establishment of the diagnosis and rapid tapering of steroids may result in a higher proportion of patients with euthyroidism.



Publication History

Received: 12 May 2019
Received: 04 August 2019

Accepted: 16 August 2019

Article published online:
23 September 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Shabb NS, Salti I. Subacute thyroiditis: Fine-needle aspiration cytology of 14 cases presenting with thyroid nodules. Diagn Cytopathol 2006; 34: 18-23
  • 2 Olah R, Hajos P, Soos Z. et al. De Quervain thyroiditis. Corner points of the diagnosis. Orv Hetil 2014; 55: 429-433
  • 3 Li LX, Wu X, Hu B. et al. Localized subacute thyroiditis presenting as a painful hot nodule. BMC Endocr Disord 2014; 14: 4
  • 4 Benbassat CA, Olchovsky D, Tsvetov G. et al. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest 2007; 30: 631-635
  • 5 Fatourechi V, Aniszewski JP, Fatourechi GZ. et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 2003; 88: 2100-2105
  • 6 Tachibana T, Orita Y, Ogawara Y. et al. Time-lag between symptom onset and laboratory findings in patients with subacute thyroiditis. Auris Nasus Larynx 2014; 41: 369-372
  • 7 Park SY, Kim EK, Kim MJ. et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol 2006; 7: 229-234
  • 8 Garcia Solano J, Gimenez Bascunana A, Sola Perez J. et al. Fine-needle aspiration of subacute granulomatous thyroiditis (De Quervain's thyroiditis): A clinico-cytologic review of 36 cases. Diagn Cytopathol 1997; 16: 214-220
  • 9 Alfadda AA, Sallam RM, Elawad GE. et al. Subacute thyroiditis: Clinical presentation and long term outcome. Int J Endocrinol 2014; 2014: 794943
  • 10 Bindra A, Braunstein GD. Thyroiditis. Am Fam Physician 2006; 73: 1769-1776
  • 11 Nishihara E, Ohye H, Amino N. et al. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 2008; 47: 725-729
  • 12 Schenke S, Klett R, Braun S. et al. Thyroiditis de Quervain – Are there predictive factors for long-term hormone-replacement?. Nuklearmedizin 2013; 52: 137-140
  • 13 Nyulassy S, Hnilica P, Buc M. et al. Subacute (de Quervain's) thyroiditis: Association with HLA-Bw35 antigen and abnormalities of the complement system, immunoglobulins and other serum proteins. J Clin Endocrinol Metab 1977; 45: 270-274
  • 14 Ohsako N, Tamai H, Sudo T. et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J Clin Endocrinol Metab 1995; 80: 3653-3656
  • 15 Kobayashi N, Tamai H, Nagai K. et al. Studies on the pathogenesis of subacute thyroiditis.Nihin Naibunpi Gakkai Zasshi 1985; 61: 737-743
  • 16 Stasiak M, Tymoniuk B, Stasiak B. et al. The risk of recurrence of subacute thyroiditis is HLA-dependent. Int J Mol Sci 2019; 20: 1089
  • 17 Kubota S, Nishihara E, Kudo T. et al. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid 2013; 23: 269-272
  • 18 Mizukoshi T, Noguchi S, Murakami T. et al. Evaluation of recurrence in 36 subacute thyroiditis patients managed with prednisolone. Intern Med 2001; 40: 292-295
  • 19 Topuzovic N, Smoje J, Karner I. The therapeutic approach in subacute (de Quervain’s) thyroiditis. J Nucl Med 1997; 38: 1665
  • 20 Omori N, Omori K, Takano K. Association of the ultrasonographic findings of subacute thyroiditis with thyroid pain and laboratory findings. Endocr J 2008; 55: 583-588
  • 21 Kunz A, Blank W, Braun B. De Quervain's subacute thyroiditis - colour Doppler sonography findings. Ultraschall Med 2005; 26: 102-106
  • 22 Vural C, Nadir P, Gök ND. et al. Subacute granulomatous (De Quervain’s) thyroiditis: Fine-needle aspiration cytology and ultrasonographic characteristics of 21 cases. Cytojournal 2015; 12: 9
  • 23 Tajiri J, Noguchi S, Morita M. et al. Serum sialic acid levels in the diagnosis and follow-up of subacute granulomatous thyroiditis. Endocr J 1993; 40: 83-87
  • 24 Zein EF, Karaa SE, Megarbane A. Familial occurrence of painful subacute thyroiditis associated with human leukocyte antigen-B35. Presse Med 2007; 36: 808-809
  • 25 Tamai H, Goto H, Uno H. et al. HLA in Japanese patients with subacute (De Quervain's) thyroiditis. Tissue Antigens 1984; 24: 58-59
  • 26 Aydin O, Apaydin FD, Bozdogan R. et al. Cytological correlation in patients who have a pre-diagnosis of thyroiditis ultrasonographically. Endr Res 2003; 29: 97-106
  • 27 Bibbo M, Wilbur D. Thyroid. In Bibbo M, Wilbur D. editors Comprehensive Cytopathology. 3rd ed. Philadelphia, PA: WB. Saunders Company; 2008: pp 633–670
  • 28 Krishna PK, Vishal S. Treatment of acute painful thyroiditis with low dose prednisolone: A study on patients from western Nepal. J Clin Diagn Res 2015; 9: MC01-MC03